--- title: "YD Bio (YDES) stock listing, news and investor profile" url: "https://aibio.space/companies/yd-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "YD Bio Ltd (NASDAQ: YDES), United States. Listing facts, related biotech companies and news on aibio.space." --- YDES YD Bio Ltd NASDAQ · United States # YD Bio (YDES) news YD Bio Ltd is a public biotech or pharmaceutical company listed on NASDAQ under the ticker YDES, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest YD Bio news We have not published a story on YD Bio yet. When there is news, it will appear here. ## YD Bio at a glance - **Ticker**: YDES - **Listing**: NASDAQ - **Country**: United States - **Cash, Dec 31, 2025**: $6.0 million ### Related companies - [VOLITIONRX LTD](https://aibio.space/companies/volitionrx/) NYSE: VNRX - [SANUWAVE Health](https://aibio.space/companies/sanuwave-health/) NASDAQ: SNWV - [EXOZYMES INC.](https://aibio.space/companies/exozymes/) NASDAQ: EXOZ - [Pulmonx](https://aibio.space/companies/pulmonx/) NASDAQ: LUNG - [20/20 Biolabs](https://aibio.space/companies/20-20-biolabs/) NASDAQ: AIDX - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) NASDAQ: CARL - [ALPHA PRO TECH LTD](https://aibio.space/companies/alpha-pro-tech/) NYSE: APT - [Prenetics Global](https://aibio.space/companies/prenetics-global/) NASDAQ: PRE ### Also on NASDAQ - [EXOZYMES INC.](https://aibio.space/companies/exozymes/) EXOZ - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) AMRX - [electroCore](https://aibio.space/companies/electrocore/) ECOR - [Exicure](https://aibio.space/companies/exicure/) XCUR - [Talphera](https://aibio.space/companies/talphera/) TLPH - [Fulgent Genetics](https://aibio.space/companies/fulgent-genetics/) FLGT ## What YD Bio does YD Bio Ltd is a publicly listed biotechnology company that completed its business combination with Breeze and YD Biopharma on August 28, 2025. Its business covers regulated diagnostics, life science clinical services and healthcare product commercialization. Its oncology testing programs in the United States use DNA methylation-based tests offered as laboratory developed tests under a CLIA framework, with CLIA-certified and CAP-accredited laboratory partner EG BioMed. The company says it has not yet obtained FDA clearance or approval for any of its cancer detection test products and has not conducted clinical trials of them. It also provides regulated life science distribution and clinical trial supply chain services, ocular health product commercialization in the United States, and consumer healthcare distribution in Asia. It holds an exclusive sublicense to methylation analysis technology for breast cancer detection under a patent licensing and technology transfer agreement between EG BioMed Co., LTD. and Yong Ding Biopharm Co., Ltd. The company has also signed a non-binding memorandum of understanding to merge with EG BioMed, a letter of intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., and a strategic alliance with YC Biotech Co., Ltd. on FDA submissions. | Product or program | What it is | Stage | |---|---|---| | DNA methylation-based cancer detection tests | Oncology tests offered as laboratory developed tests to licensed providers | not yet FDA cleared or approved | | EG Telehealth Platform | Online portal with a telehealth physician network to support diagnostic service delivery | launched March 31, 2026 | | Clinical trial supply chain services | Procurement, logistics coordination and compliance support for clinical development | | Summarised from the company's [20-F filed Apr 30, 2026](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/ea0286160-20f_ydbio.htm). ## YD Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$596,817](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | [$510,360](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | | Research and development | [$1.6 million](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | [$491,353](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | | Net income (loss) | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | [-$1.4 million](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | | Cash from operations | [-$6.6 million](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | [-$1.2 million](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | | Cash and equivalents | [$6.0 million](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | [$3.1 million](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $6.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about YD Bio What is the ticker symbol of YD Bio? YD Bio Ltd trades under the ticker YDES on NASDAQ. Where is YD Bio listed? YD Bio Ltd is listed on NASDAQ. Which country or territory is YD Bio listed under? Our directory records YD Bio Ltd under United States. Does aibio.space cover YD Bio? aibio.space lists YD Bio Ltd among 2,820 public biotech companies and publishes its news here as stories appear. What does YD Bio develop? YD Bio Ltd is a publicly listed biotechnology company that completed its business combination with Breeze and YD Biopharma on August 28, 2025. Its business covers regulated diagnostics, life science clinical services and healthcare product commercialization. What is DNA methylation-based cancer detection tests from YD Bio? DNA methylation-based cancer detection tests: Oncology tests offered as laboratory developed tests to licensed providers Stage: not yet FDA cleared or approved. What is EG Telehealth Platform from YD Bio? EG Telehealth Platform: Online portal with a telehealth physician network to support diagnostic service delivery Stage: launched March 31, 2026. What was YD Bio's revenue last year? $596,817 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is YD Bio profitable? YD Bio Ltd reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2025, and used $6.6 million of cash in operations, per its annual report to the SEC. How much does YD Bio spend on research and development? $1.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does YD Bio have? $6.0 million in cash at Dec 31, 2025, per its 20-F. ## Investor discussion: YD Bio Members talk about YD Bio (YDES). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at YD Bio, newest first. Each line links the filing it comes from. 1. 2026-09-01 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2011674/000121390026095815/ea030356301ex99-1.htm) 2. 2026-04-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/ea0286160-20f_ydbio.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:YDES on TradingView](https://www.tradingview.com/symbols/NASDAQ-YDES/). ## Listing details YD Bio Ltd is a public biotech or pharmaceutical company listed on NASDAQ under the ticker YDES, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: YD Bio Ltd - **Ticker**: YDES - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/yd-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "YD Bio (YDES) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/yd-bio/